id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-D-4751-0013,FDA,FDA-2019-D-4751,FDA Reauthorization Act Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs; Guidance for Industry; Availability,Notice,Notice of Availability,2021-05-25T04:00:00Z,2021,5,2021-05-25T04:00:00Z,,2021-05-25T12:41:42Z,2021-11022,0,0,0900006484b333db
FDA-2019-D-4751-0014,FDA,FDA-2019-D-4751,FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act; Guidance for Industry,Other,Guidance,2021-05-25T04:00:00Z,2021,5,2021-05-25T04:00:00Z,,2024-11-06T23:47:24Z,,1,0,0900006484b332a2
FDA-2019-D-4751-0003,FDA,FDA-2019-D-4751,Request for Extension from Biotechnology Innovation Organization (BIO),Other,Request for Extension,2019-12-30T05:00:00Z,2019,12,2019-12-30T05:00:00Z,,2019-12-30T20:17:17Z,,0,0,090000648424d4c8
FDA-2019-D-4751-0002,FDA,FDA-2019-D-4751,FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act Guidance for Industry,Other,Guidance,2019-12-13T05:00:00Z,2019,12,2019-12-13T05:00:00Z,,2024-11-12T23:14:00Z,,1,0,090000648420cd07
FDA-2019-D-4751-0001,FDA,FDA-2019-D-4751,Food and Drug Administration Reauthorization Act Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2019-12-13T05:00:00Z,2019,12,2019-12-13T05:00:00Z,2020-02-12T04:59:59Z,2020-05-06T20:45:01Z,2019-26877,0,0,090000648420c58d